Acute Metabolic Outcomes in Diabetic Patients Hospitalized for COVID-19 (DMD-COV) (DMD-COV)

Acute Metabolic Outcomes of Diabetic Patients Hospitalized for COVID-19 in Algeria: A Prospective Cohort Study (DMD-COV)

Diabetes is a major risk factor for severe COVID-19 and poor clinical outcomes during hospitalization. However, little is known about the medium- and long-term metabolic consequences of COVID-19 in people with diabetes after hospital discharge.

The DMD-COV study is a prospective, multicenter observational cohort conducted in Algeria. Its aim is to evaluate the cardio-metabolic outcomes of adult patients with diabetes who were hospitalized for confirmed COVID-19 and survived the acute phase of the infection.

Adult patients with type 1 or type 2 diabetes will be included during hospitalization or within 30 days after hospital discharge. Participants will be followed for up to one year after discharge, with scheduled evaluations at baseline, 3 months, 6 months, and 12 months.

During follow-up, clinical, biological, and therapeutic data will be collected, including glycemic control (HbA1c), body weight, lipid profile, kidney function, and diabetes treatments. The main outcome is the proportion of patients achieving their individualized HbA1c target at 6 months and 12 months after hospitalization for COVID-19.

The results of this study will help to better understand the long-term metabolic impact of COVID-19 in people with diabetes and to improve post-COVID diabetes management.

Study Overview

• Status: Completed
• Conditions: COVID-19; Diabetes Mellitus; Post-Acute COVID-19 Syndrome
• Intervention / Treatment: Other: No intervention (observational study)

Detailed Description

The DMD-COV study is a prospective, non-interventional, multicenter cohort study conducted in Algeria. The study aims to describe the cardio-metabolic outcomes of adult patients with diabetes following hospitalization for COVID-19.

Patients with type 1 or type 2 diabetes who were hospitalized for laboratory-confirmed COVID-19 (PCR, serology, or antigen test) will be included during hospitalization or within 30 days after discharge. The study does not interfere with routine clinical care, and all therapeutic decisions are made according to usual medical practice.

Approximately 200 patients will be enrolled across multiple university hospital centers. Participants will be followed for one year, with four scheduled visits: at baseline (inclusion), 3 months, 6 months, and 12 months after hospital discharge.

Data collected during the study include demographic characteristics, diabetes history, comorbidities, COVID-19 severity markers, duration of hospitalization, and treatments received during the acute phase, including corticosteroids and anticoagulants. At each follow-up visit, clinical parameters (weight, body mass index, waist circumference), glycemic control (HbA1c, fasting plasma glucose), lipid profile, renal function, and diabetes treatments will be recorded.

The primary outcome is glycemic control, assessed by the proportion of patients achieving their individualized HbA1c target at 6 months and 12 months after hospitalization. Secondary outcomes include changes in HbA1c over time, evolution of diabetes treatments, weight changes, lipid profile, renal function, and identification of factors associated with good glycemic control after COVID-19.

This study will provide valuable real-world data on the metabolic evolution of patients with diabetes after COVID-19 and may contribute to optimizing long-term follow-up strategies in this population.

• Study Type: Observational
• Enrollment (Actual): 201

Contacts and Locations

Study Locations

• Algeria
  • El Biar
    • Algiers, El Biar, Algeria
      • Djillali Belkhenchir Public Hospital (formerly Birtraria)

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Adult patients with type 1 or type 2 diabetes who were hospitalized for confirmed COVID-19 and followed after hospital discharge to assess cardio-metabolic outcomes.

Description

Inclusion Criteria:

• Age 18 years or older
• Diagnosis of type 1 or type 2 diabetes mellitus
• Hospitalization for laboratory-confirmed COVID-19
• Inclusion during hospitalization or within 30 days after hospital discharge
• Signed informed consent

Exclusion Criteria:

• Age under 18 years
• Absence of diabetes mellitus
• Refusal or inability to provide informed consent

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Diabetic patients hospitalized for COVID-19; Adult patients with type 1 or type 2 diabetes who were hospitalized for confirmed COVID-19 and followed prospectively after hospital discharge to assess cardio-metabolic outcomes over a one-year period.	Other: No intervention (observational study); This is a non-interventional observational study. No experimental or therapeutic intervention is assigned as part of the study protocol. All medical care and treatments are provided according to routine clinical practice.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Glycemic control after hospitalization for COVID-19	Proportion of patients achieving their individualized HbA1c target according to international diabetes guidelines.	6 months and 12 months after hospital discharge

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in HbA1c over follow-up	Mean change in HbA1c from baseline to 3 months, 6 months, and 12 months after hospital discharge.	Baseline, 3 months, 6 months, and 12 months
Change in body weight and body mass index	Change in body weight and body mass index (BMI) during follow-up.	Baseline, 3 months, 6 months, and 12 months
Evolution of diabetes treatment	Changes in diabetes treatment regimen during follow-up, including insulin initiation or intensification and modification of oral or injectable antidiabetic therapies.	Up to 12 months after hospital discharge
Changes in lipid profile and renal function	Changes in lipid profile parameters and renal function during follow-up after COVID-19 hospitalization.	Baseline, 6 months, and 12 months
Factors associated with poor glycemic control after COVID-19	Identification of clinical and therapeutic factors associated with failure to achieve individualized HbA1c targets after hospitalization for COVID-19.	Up to 12 months after hospital discharge

Collaborators and Investigators

• Sponsor: Algerian Society of Diabetology
• Collaborators: Novo Nordisk A/S; Algerian Society of Internal Medicine

Study record dates

Study Major Dates

• Study Start (Actual): January 28, 2021
• Primary Completion (Actual): August 24, 2022
• Study Completion (Actual): August 24, 2022

Study Registration Dates

• First Submitted: April 26, 2026
• First Submitted That Met QC Criteria: April 26, 2026
• First Posted (Actual): April 30, 2026

Study Record Updates

• Last Update Posted (Actual): April 30, 2026
• Last Update Submitted That Met QC Criteria: April 26, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Keywords: Diabetes; HbA1c; COVID-19; Metabolic Syndrome; Glycemic Control; Post-COVID; Hospitalized Patients; Prospective Cohort; Cardiometabolic Outcomes; Algeria
• Additional Relevant MeSH Terms: Post-Infectious Disorders; Endocrine System Diseases; Pathologic Processes; Chronic Disease; Disease Attributes; Metabolic Diseases; Respiratory Tract Infections; Infections; RNA Virus Infections; Virus Diseases; Respiratory Tract Diseases; Lung Diseases; Glucose Metabolism Disorders; Pneumonia, Viral; Pneumonia; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; Insulin Resistance; Hyperinsulinism; Pathological Conditions, Signs and Symptoms; Nutritional and Metabolic Diseases; COVID-19; Post-Acute COVID-19 Syndrome; Metabolic Syndrome; Diabetes Mellitus; Investigative Techniques; Methods; Observation
• Other Study ID Numbers: DMD-COV

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No